Investigating the effectiveness of L-arginine in reducing duration of hospitalization and pain intensity of children with sickle cell disease compared to placebo.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170112031891N2

Enrollment

120

Registered

2018-04-09

Start date

2017-06-22

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle cell disease. Other sickle-cell disorders with crisis

Interventions

Intervention 1: L-arginine drug orally or intravenously at a dose of 100 mg / kg, three times a day until discharge from hospital. Intervention 2: Placebo drug orally or intravenously at a dose of 100

Eligibility

Sex/Gender

All

Age

3 Years to 20 Years

Inclusion criteria

Inclusion criteria: Patients affected by sickle cell disease Age 3 to 20 years

Exclusion criteria

Exclusion criteria: liver failure Renal failure Under 5 grams of hemoglobin per deciliter Patients in need of immediate infusion of blood Pregnancy History of hospitalization more than 10 times in the hospital A history of opiate dependence Sensitivity to arginine

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: A week. Method of measurement: Based on Visual Analogue Scale and Faces Pain.;Time of Hospitalization. Timepoint: The duration of treatment. Method of measurement: The duration of Hospitalization.	—

Secondary

Measure	Time frame
Pharmaceutical allergy. Timepoint: The duration of treatment. Method of measurement: Clinical observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Nima Mahmoudzadeh

Ahvaz University of Medical Sciences

Nima87433@yahoo.com+98 61337430019

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026